Prescient Therapeutics Ltd
ASX:PTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prescient Therapeutics Ltd
Income from Continuing Operations
Prescient Therapeutics Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prescient Therapeutics Ltd
ASX:PTX
|
Income from Continuing Operations
-AU$8.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-18%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Income from Continuing Operations
-$94.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Income from Continuing Operations
$1.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Income from Continuing Operations
-AU$9.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Income from Continuing Operations
-AU$7.1m
|
CAGR 3-Years
53%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Income from Continuing Operations
-AU$48.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-30%
|
|
Prescient Therapeutics Ltd
Glance View
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).
See Also
What is Prescient Therapeutics Ltd's Income from Continuing Operations?
Income from Continuing Operations
-8.9m
AUD
Based on the financial report for Dec 31, 2025, Prescient Therapeutics Ltd's Income from Continuing Operations amounts to -8.9m AUD.
What is Prescient Therapeutics Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-18%
Over the last year, the Income from Continuing Operations growth was -25%. The average annual Income from Continuing Operations growth rates for Prescient Therapeutics Ltd have been -18% over the past three years , -21% over the past five years , and -18% over the past ten years .
